PEAK6 Group’s Haemonetics HAE Stock Holding History

PEAK6 Group’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$359K	Buy	+4,000	New	+$338K	﹤0.01%	2867
2018 Q1	–	Sell	-11,500	Closed	-$668K	–	4547
2017 Q4	$668K	Buy	+11,500	New	+$606K	﹤0.01%	2241
2015 Q2	–	Sell	-10,300	Closed	-$463K	–	5191
2015 Q1	$463K	Buy	+10,300	New	+$431K	﹤0.01%	2620
2014 Q2	–	Sell	-700	Closed	-$23K	–	4794
2014 Q1	$23K	Buy	+700	New	+$26.8K	﹤0.01%	4544

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

PEAK6 Group's HAE Position: Q2 2018 in Review

PEAK6 Group opened a new position in Haemonetics (HAE) in Q2 2018: 3,071 shares worth $275K. The stake represents ﹤0.01% of the portfolio and ranks #3094 among its holdings. This is a return to the name: PEAK6 Group previously reported a position in HAE as recently as Q4 2016.

PEAK6 Group first reported a position in HAE in Q1 2014 and has held it in 4 quarters since. 293 funds tracked by Wall St. Rank hold HAE as of Q2 2018.

PEAK6 Group held 3,071 shares of Haemonetics worth $275K as of Q2 2018.
Haemonetics was a new PEAK6 Group position in Q2 2018.
Haemonetics made up ﹤0.01% of PEAK6 Group's portfolio in Q2 2018, its #3094 holding.
PEAK6 Group first reported a position in Haemonetics in Q1 2014 and has held it in 4 quarters since.
293 funds tracked by Wall St. Rank held Haemonetics as of Q2 2018.

Based on PEAK6 Group's 13F filing for Q2 2018, filed 15 Aug 2018.